**Supplementary File 5: Antibiotics Discovery Pipeline for Priority Pathogens.**

|  |  |  |
| --- | --- | --- |
| **S. No.** | **Product Name** | **Phase of development** |
|  | Afabicin | II |
|  | Arx-1796 | I |
|  | Benapenem | II |
|  | Durlobactam+ Sulbactam | III |
|  | Ebl-1003 | I |
|  | Enmetazobactam + Cefepime | III |
|  | Etx0282 + Cefpodoxime | I |
|  | Gepotidacin | III |
|  | Kbp-7072 | I |
|  | Nacubactam + Meropenem | I |
|  | Nafithromycin | II |
|  | Plg0206 | I |
|  | Qpx7728 + Qpx2014 | I |
|  | Spr-206 | I |
|  | Sulopenem, Sulopenem Etzadroxil/Probenecid | III |
|  | Taniborbactam = Cefepime | III |
|  | Tnp-2092 | II |
|  | Tnp-2198 | I |
|  | Tp-271 | I |
|  | Tp-6076 | I |
|  | Txa709 | I |
|  | Vnrx-7145 + Ceftibiten | I |
|  | Zidebactam + Cefepime | I |
|  | Zoliflodacin | III |
| Source: WHO 2021: Source: global-observatory on health research and development (https://www.who.int/observatories/global-observatory-on-health-research-and-development) | | |